Program to understand and treat Hypertrophic Cardiomyopathy in Egypt
Egyptian Hypertrophic Cardiomyopathy Program
This study is trying to understand Hypertrophic Cardiomyopathy in Egypt by looking at how common it is, how it affects people, and finding better treatment options for patients and their families.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Sex | All |
| Sponsor | Magdi Yacoub Heart Foundation Academic / other |
| Locations | 1 site (Aswān) |
| Trial ID | NCT05884892 on ClinicalTrials.gov |
What this trial studies
The Egyptian Hypertrophic Cardiomyopathy Program aims to define the incidence, severity, phenotype, and genotype of Hypertrophic Cardiomyopathy (HCM) in Egypt. It involves characterizing large cohorts of patients with inherited muscle disease and their relatives, while also providing tailored treatment strategies that include medical, surgical, and interventional procedures. The program focuses on studying the basic mechanisms of the disease at a molecular level and aims to train local cardiologists and surgeons in advanced diagnostic and management techniques. Additionally, it seeks to explore the role of microvascular coronary arteries in disease progression.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with Hypertrophic Cardiomyopathy and their family members who consent to participate.
Not a fit: Patients who refuse to consent to participate in the registry will not benefit from this program.
Why it matters
Potential benefit: If successful, this program could lead to improved diagnosis and personalized treatment strategies for patients with Hypertrophic Cardiomyopathy.
How similar studies have performed: While similar studies have been conducted, this program's specific focus on the Egyptian population and its comprehensive approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients diagnosed with hypertrophic cardiomyopathy (index patients) who are willing and consented to participate in the registry. * All family members of index patients who are willing and consented to participate in the registry. Exclusion Criteria: * Refusal to consent to participate in the registry program.
Where this trial is running
Aswān
- Aswan Heart Centre - Magdi Yacoub Heart Foundation — Aswān, Egypt (Recruiting)
Study contacts
- Study coordinator: Magdi H Yacoub, FRS OM
- Email: m.yacoub@imperial.ac.uk
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.